Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.
Of Interest
New Algorithm Proposes Targeted Lipase Monitoring for Pancreatic Adverse Events In Melanoma
Researchers recommend limiting routine lipase tests to symptomatic patients or those with radiographic signs of pancreatic injury.
Podcast: JCO Article Insights: Nivolumab + Relatlimab v Nivolumab + Ipilimumab in Melanoma
In this JCO Article Insights episode, Rohit Singh provides a summary on “First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data", by Long et al, published in the November issue of the Journal of Clinical Oncology. The article provides insights into the use of the two dual immune checkpoint inhibitor regimens in patients with untreated advanced melanoma.
Tumor characteristics found to differ for melanomas in children, teens and young adults
Tumor characteristics differ significantly among pediatric and adolescent and young adult (AYA) patients with melanoma, with decreasing incidence rates seen among young patients with cutaneous melanoma, according to a study published online Nov. 15 in the Journal of the American Academy of Dermatology.